Publications found:
36,694
Sort by:
Adalimumab-Biosimilars Insight, 2022
US$ 2,000.00
This report can be delivered to the clients within 72-96 hours DelveInsight’s, “Adalimumab– Biosimilar 2022,” report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline...
January 2022
90 pages
Bevacizumab-Biosimilars Insight, 2022
US$ 2,000.00
This report can be delivered to the clients within 96-120 hours DelveInsight’s, “Bevacizumab– Biosimilar 2022,” report provides comprehensive insights about 40+ companies and 40+ marketed and pipeli...
January 2022
125 pages
Filgrastim - Biosimilar Insight, 2022
US$ 2,000.00
This report can be delivered to the clients within 48-72 hours DelveInsight’s, “Filgrastim– Biosimilar 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline...
January 2022
70 pages
Infliximab-Biosimilars Insight, 2022
US$ 2,000.00
This report can be delivered to the clients within 72-96 hours DelveInsight’s, “Infliximab– Biosimilar 2022,” report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline...
January 2022
90 pages
Insulin Glargine- - Biosimilar Insight, 2022
US$ 2,000.00
This report can be delivered to the clients within 72-96 hours DelveInsight’s, “Insulin Glargine– Biosimilar 2022,” report provides comprehensive insights about 10+ companies and 10+ marketed and pi...
January 2022
90 pages
Interferon - Biosimilar Insight, 2022
US$ 1,000.00
This report can be delivered to the clients within 48-72 hours DelveInsight’s, “Interferon– Biosimilar 2022,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline...
January 2022
70 pages
Ranibizumab-Biosimilars Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 72-96 hours DelveInsight’s, “Ranibizumab– Biosimilar 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipelin...
January 2022
90 pages
Rituximab-Biosimilars Insight, 2022
US$ 2,500.00
This report can be delivered to the clients within 96-120 hours DelveInsight’s, “Rituximab– Biosimilar 2022,” report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline...
January 2022
125 pages
Somatotropin - Biosimilar Insight, 2022
US$ 1,000.00
This report can be delivered to the clients within 48-72 hours DelveInsight’s, “Somatropin– Biosimilar 2022,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline...
January 2022
70 pages
Trastuzumab-Biosimilars Insight, 2022
US$ 2,500.00
This report can be delivered to the clients within 96-120 hours DelveInsight’s, “Trastuzumab– Biosimilar 2022,” report provides comprehensive insights about 35+ companies and 35+ marketed and pipeli...
January 2022
125 pages
Biliary Atresia (BA) - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Biliary Atresia (BA) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, h...
January 2022
60 pages
Follicular Lymphoma - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Follicular Lymphoma - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, hi...
January 2022
60 pages
Hypofibrinogenemia - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Hypofibrinogenemia - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, his...
January 2022
60 pages
West Syndrome - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'West Syndrome - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historic...
January 2022
60 pages
Cyclin-dependent-kinase-inhibitors - Pipeline Insight, 2022
US$ 2,500.00
This report can be delivered to the clients within 3-4 working days DelveInsight’s, “Cyclin-dependent-kinase-inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 40+ com...
January 2022
150 pages
VAP-1 Inhibitors - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “VAP-1 Inhibitors- Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline dru...
January 2022
60 pages
Anti-CD22 Therapies - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “Anti-CD22 Therapies - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline...
January 2022
60 pages
Anti-CD30 Therapies - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “Anti-CD30 Therapies - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline...
January 2022
60 pages
AXL Kinase Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “AXL Kinase Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipelin...
January 2022
60 pages
LRRK2 Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor - Pipeline Insight, 2021,” report provides comprehensive insights about 8+...
January 2022
60 pages
